

Appendix Table F154. Nonsignificant differences in comparative effectiveness of flexible-dose solifenacin 5/10 mg with and without simplified bladder training in patients with overactive bladder syndrome (results from individual randomized controlled clinical trial)⁶⁵

Outcome	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)
Mild adverse effects	66/323	71/320	0.92 (0.68; 1.24)	-0.018 (-0.081; 0.046)
Moderate adverse effects	68/323	66/320	1.02 (0.76; 1.38)	0.004 (-0.059; 0.067)
Serious adverse effects	6/323	6/320	0.99 (0.32; 3.04)	0.000 (-0.021; 0.021)
Severe adverse effects	16/323	12/320	1.32 (0.64; 2.75)	0.012 (-0.019; 0.044)
Treatment-related adverse effects	83/323	81/320	1.02 (0.78; 1.32)	0.004 (-0.064; 0.071)
Constipation	14/323	24/320	0.58 (0.30; 1.10)	-0.032 (-0.068; 0.005)
Dry mouth	52/323	45/320	1.14 (0.79; 1.65)	0.020 (-0.035; 0.076)
Dyspepsia	6/323	8/320	0.74 (0.26; 2.12)	-0.006 (-0.029; 0.016)
Eye disorders	15/323	14/320	1.06 (0.52; 2.16)	0.003 (-0.029; 0.035)
Gastrointestinal disorders	77/323	85/320	0.90 (0.69; 1.17)	-0.027 (-0.094; 0.040)
General disorders and administration site	13/323	12/320	1.07 (0.50; 2.32)	0.003 (-0.027; 0.033)
Influenza and infections	52/323	45/320	1.14 (0.79; 1.65)	0.020 (-0.035; 0.076)
Musculoskeletal and connective tissue disorders	15/323	15/320	0.99 (0.49; 1.99)	0.000 (-0.033; 0.032)
Nervous system disorders	19/323	15/320	1.25 (0.65; 2.43)	0.012 (-0.023 ;0.047)
Psychiatric disorders	8/323	4/320	1.98 (0.60; 6.51)	0.012 (-0.009; 0.033)
Renal and urinary disorders	9/323	7/320	1.27 (0.48; 3.38)	0.006 (-0.018; 0.030)
Respiratory, thoracic, and mediastinal disorders	7/323	8/320	0.87 (0.32; 2.36)	-0.003 (-0.027 ;0.020)
Skin/subcutaneous disorders	11/323	5/320	2.18 (0.77; 6.20)	0.018 (-0.006; 0.042)